Teva Copaxone Nears U.K. Approval, But NICE To Refuse MS Drug Payment
Teva is expecting U.K. licensure of its multiple sclerosis drug Copaxone (glatiramer) in July for reduction in frequency of relapse in relapsing/remitting MS, the company indicated.
You may also be interested in...
Both Bristol-Myers Squibb's Taxol and Aventis' Taxotere have been recommended for routine use by U.K.' s National Institute for Clinical Excellence for advanced second-line breast cancer treatment, following a successful appeal by Bristol.
Teva's smooth performance in the multiple sclerosis market is shoring up the company in a difficult environment for biopharmaceutical stocks.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011